Skip to main content

Miguel Chillon Rodriguez

Dr. M. Chillon has been a senior ICREA researcher since 2001 and Director of the UAB-VHIR Joint Unit since 2017. He obtained his doctorate in Genetics at Hospital Duran i Reynals in 1994. Dr. M. Chillon is Director of the Production Unit of Vectors since 2004, Associate Professor at the UAB since 2005, Principal Investigator of the VHIR since 2017, Co-Chair of the Platform for Advanced Therapies of the European organization EATRIS since 2016, coordinator of the eCORE AVANT of the VHIR since 2022, and scientific advisor of different patient organizations and biotechnological spin-offs

Institutions of which they are part

Head of group
Gene Therapy at Nervous System
Vall Hebron Institut de Recerca

Miguel Chillon Rodriguez

Institutions of which they are part

Head of group
Gene Therapy at Nervous System
Vall Hebron Institut de Recerca

Dr. M. Chillon has been a senior ICREA researcher since 2001 and Director of the UAB-VHIR Joint Unit since 2017. He obtained his doctorate in Genetics at Hospital Duran i Reynals in 1994. Dr. M. Chillon is Director of the Production Unit of Vectors since 2004, Associate Professor at the UAB since 2005, Principal Investigator of the VHIR since 2017, Co-Chair of the Platform for Advanced Therapies of the European organization EATRIS since 2016, coordinator of the eCORE AVANT of the VHIR since 2022, and scientific advisor of different patient organizations and biotechnological spin-offs

Dr. M. Chillon created his research group in 2001 focused from the beginning on four main objectives: (1) gene therapy for cognitive deficits associated with aging; (2) gene therapy for autoimmune diseases; (3) gene therapy for rare diseases that affect the nervous system and (4) development of more efficient gene therapy vectors. Dr. Chillon is the author of 76 scientific articles, 3 reviews, 5 book chapters, editor of 1 book (H index: 27; 3470 citations, Scopus), and has directed 14 doctoral theses (4 in progress) and 22 students of Master. In the last five years, Dr. Chillon has obtained different national and international projects such as the European Joint Program-Rare Diseases AC20/00051; Society Challenges. PID2019-104034RB-I00; Challenges Collaboration RTC2019-006879-1; RICORS of the ISCIII RD21/0017/0008; Santander Foundation (2020); CERVERA IDI-2020-0258; ALS International (2018-0512); SmartMoney-UAB (2017); and Marathon TV3, 201607.10. Regarding technology transfer, Dr. Chillon's group has generated 10 patents and founded 2 spin-off companies: NanoTherapix (2009) for gene and cell therapy for diseases of the immune system; and Klogene (2016) for gene therapy of cognitive impairments. He has also founded the Vector Production Unit (UPV) to value the knowledge generated. Currently, the UPV is the first supplier of Ad and AAV vectors to Spanish groups and has the TECNIO Quality accreditation and ISO9001:2015 accreditation. Finally, in recognition of his career, Dr. M Chillón received the "Transfer Award" in 2018 from the Social Council of the UAB.

Projects

ESTUDIO Y DESARROLLO DE LA PRIMERA PLATAFORMA TECNOLÓGICA DE ENSAYOS PARA VIRUS ADENOASOCIADOS EN TERÁPIA GÉNICA

IP: Miguel Chillon Rodriguez
Collaborators: Susana Miravet Delgado, Laia Rubio Ortega, Marina Tarrés Mercader
Funding agency: Instituto de Salud Carlos III
Funding: 296571
Reference: PMPTA22/00048
Duration: 01/01/2023 - 31/12/2024

MECPer-3D - Personalized MECP2 gene therapy using CRISPR/Cas9 technology coupled to AAV-mediated delivery in 3D cell culture and KI mice

IP: Miguel Chillon Rodriguez
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: ISCIII/ERA-NET/EJPRD/2020/CHILLON
Duration: -

Terapia génica para MECP2 personalizada utilizando la tecnología CRISPR/Cas9 junto con administración por AAV, en cultivo de células 3D y ratones KI

IP: Miguel Chillon Rodriguez
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 169097.5
Reference: AC20/00051
Duration: 01/01/2021 - 31/10/2024

Sol·licitud beques Predoctorals. Modalitat VHIR-AGAUR

IP: Miguel Chillon Rodriguez
Collaborators: Laia Perez Lasarte
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: PRED-VHIR-16-34/EDO
Duration: 01/03/2017 - 29/02/2020

Related news

Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.

Related professionals

Marta Sanchiz Cruz

Marta Sanchiz Cruz

Research technician
Infectious Diseases
Read more
Mª Eulàlia Joseph Munné

Mª Eulàlia Joseph Munné

Medium Grade Technician
General Services and Infrastructure
Manager
Read more
Jordi Giralt López de Sagred

Jordi Giralt López de Sagred

Main researcher
Read more
Anna Vilarrodona Serrat

Anna Vilarrodona Serrat

Research technician
Donation and transplantation of organs, tissues and cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.